Mesenchymal stem cells loaded with oncolytic reovirus enhances antitumor activity in mice models of colorectal cancer

2021 ◽  
pp. 114644
Author(s):  
Abouzar Babaei ◽  
Hoorieh Soleimanjahi ◽  
Masoud Soleimani ◽  
Ehsan Arefian
Cancers ◽  
2018 ◽  
Vol 10 (11) ◽  
pp. 446 ◽  
Author(s):  
Jui-Hua Lu ◽  
Bou-Yue Peng ◽  
Chun-Chao Chang ◽  
Navneet Dubey ◽  
Wen-Cheng Lo ◽  
...  

Cancer is a leading cause of mortality and a major public health problem worldwide. For biological therapy against cancer, we previously developed a unique immunotherapeutic platform by combining mesenchymal stem cells with an antigen-specific protein vaccine. However, this system possesses a few limitations, such as improperly immortalized mesenchymal stem cells (MSCs) along with transfected oncogenic antigens in them. To overcome the limitations of this platform for future clinical application, we freshly prepared primary adipose-derived stem cells (ADSCs) and modified the E7’ antigen (E7’) as a non-oncogenic protein. Either subcutaneously co-inoculated with cancer cells or systemically administered after tumor growth, ADSC labeled with enhanced green fluorescent protein (eGFP) and combined with modified E7’ (ADSC-E7’-eGFP) cells showed significant antitumor activity when combined with the protein vaccine in both colon and lung cancer in mice. Specifically, this combined therapy inhibited tumor through inducing cell apoptosis. The significantly reduced endothelial cell markers, CD31 and vascular endothelial growth factor (VEGF), indicated strongly inhibited tumor angiogenesis. The activated immune system was demonstrated through the response of CD4+ T and natural killer (NK) cells, and a notable antitumor activity might be contributed by CD8+ T cells. Conclusively, these evidences imply that this promising immunotherapeutic platform might be a potential candidate for the future clinical application against cancer.


2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Xiao-Bing Wu ◽  
Yang Liu ◽  
Gui-Hua Wang ◽  
Xiao Xu ◽  
Yang Cai ◽  
...  

2007 ◽  
Vol 18 (7) ◽  
pp. 627-641 ◽  
Author(s):  
Tanja Hakkarainen ◽  
Merja Särkioja ◽  
Petri Lehenkari ◽  
Susanna Miettinen ◽  
Timo Ylikomi ◽  
...  

Author(s):  
Ruohang He ◽  
Chaoqun Han ◽  
Ying Li ◽  
Wei Qian ◽  
Xiaohua Hou

BackgroundMesenchymal stem cells (MSCs) treatment showed promising results in inflammatory bowel disease in both rodent models and patients. Nevertheless, previous studies conducted conflicting results on preclinical tumor models treated with MSCs concerning their influence on tumor initiation and progression. This study is designed to demonstrate the role of bone marrow-derived MSCs and the potential mechanism in the colitis-associated colon cancer (CAC) model.MethodsBone marrow-derived MSCs were isolated from green fluorescent protein-transgenic mice, cultured, and identified by flow cytometry. Azoxymethane and dextran sulfate sodium were administrated to establish the CAC mouse model, and MSCs were infused intraperitoneally once per week. The mice were weighed weekly, and colon length, tumor number, and average tumor size were assessed after the mice were killed. MSC localization was detected by immunofluorescence staining; tumor cell proliferation and apoptosis were measured by immunohistochemistry staining of Ki-67 and terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling assay, respectively. The colonic tumor tissues were isolated for RNA-seq, and fecal samples were collected for 16S ribosomal RNA sequencing of the microbiome.ResultsAfter injection intraperitoneally, MSCs migrated to the intestine and inhibited the initiation of colitis-associated colorectal cancer. This inhibition effect was marked by less weight loss, longer colon length, and reduced tumor numbers. Moreover, MSCs reduced tumor cell proliferation and induced tumor cell apoptosis. Furthermore, MSCs could inhibit chronic inflammation assessed by RNA-sequencing and promote gut microbiome normalization detected by 16S ribosomal RNA sequencing.ConclusionThe results proved that MSCs could migrate to the colon, inhibit chronic inflammation, and regulate gut microbiome dysbiosis to suppress the development of CAC.


2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Yan Wang ◽  
Changkun Lin

Objective. Exosomes (exo) which contain proteins, microRNAs (miRNAs), and other bioactive substances can participate in intercellular signal transduction and material transport. Bone marrow mesenchymal stem cells (BMSCs) have a strong ability to produce exosomes. The purpose of this study was to observe the effect of hBMSCs-derived-exo miR-22-3p on proliferation and invasion of colorectal cancer (CRC) cells and to explore its mechanism. Methods. miR-22-3p and RAS oncogene family (RAP2B) expression was detected using qRT-PCR or Western blotting. Their interaction was confirmed by dual luciferase activity assay. Effects of miR-22-3p on cell proliferation and invasion were evaluated by CCK-8 and Transwell assay, respectively. Exosomes were extracted by the ultracentrifugation and identified through electron microscopy and Western blotting. Results. In CRC tissues and cells, downregulation of miR-22-3p and upregulation of RAP2B were observed. According to the analysis of dual luciferase activity, RAP2B was a target gene of miR-22-3p. In addition, miR-22-3p obviously repressed the cells proliferation and invasion via mediating RAP2B/PI3K/AKT pathway. Coculture experiments indicated that miR-22-3p derived from hBMSCs-exo had inhibition effects on SW480 cell proliferation and invasion. Conclusions. Collectively, miR-22-3p from hBMSCs-exo might impede CRC progression, which emphasized the potential of hBMSCs-exo-miR-22-3p as CRC treatment in the future.


Life Sciences ◽  
2020 ◽  
Vol 261 ◽  
pp. 118369
Author(s):  
Elnaz Bagheri ◽  
Khalil Abnous ◽  
Sara Amel Farzad ◽  
Seyed Mohammad Taghdisi ◽  
Mohammad Ramezani ◽  
...  

2015 ◽  
Vol 363 (2) ◽  
pp. 156-165 ◽  
Author(s):  
Ana Entrena ◽  
Alberto Varas ◽  
Miriam Vázquez ◽  
Gustavo J. Melen ◽  
Lidia M. Fernández-Sevilla ◽  
...  

Gene Therapy ◽  
2011 ◽  
Vol 18 (5) ◽  
pp. 488-495 ◽  
Author(s):  
S H Seo ◽  
K S Kim ◽  
S H Park ◽  
Y S Suh ◽  
S J Kim ◽  
...  

Gut ◽  
2012 ◽  
Vol 62 (4) ◽  
pp. 550-560 ◽  
Author(s):  
Astrid De Boeck ◽  
Patrick Pauwels ◽  
Karen Hensen ◽  
Jean-Luc Rummens ◽  
Wendy Westbroek ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document